10-Q · May 12, 2026
Firefly Neuroscience reported substantial growth in revenue for Q1 2026, achieving $485,000 compared to just $43,000 in the same period last year, marking an increase of over 1020%. However, the company continues to…
Earnings analysis · 10-Q
AIFF earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment data, or quantitative guidance, so financial trends cannot be assessed from this filing extract. The primary…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment data, or quantitative guidance, so financial trends cannot be assessed from this filing extract. The primary disclosure is a control failure: as of June 30, 2026, management concluded that disclosure controls and internal control over financial reporting were not effective and identified 2 material weaknesses. Remediation is targeted for Q4 2026, but completion depends on further evaluation and testing.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control remediation targeted for Q4 2026
Management expects to complete the design and implementation of remediation controls during 2026, with a projected remediation date of Q4 2026.
-
No identified financial misstatements
The material weaknesses did not result in any identified misstatements, and the filing states there were no changes to previously reported financial results.
-
No quarterly control changes
There were no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No equity sales or repurchases
The company reported no unregistered equity sales during the three months ended June 30, 2026 and made no common-stock repurchases during that period.
-
No material litigation identified
The filing states that no material legal proceedings or claims are currently known that would adversely affect business, financial condition, or operating results.
What to watch
-
Ineffective disclosure controls
As of June 30, 2026, the CEO and CFO concluded that disclosure controls and procedures were not effective. Management identified 2 material weaknesses in internal control over financial reporting.
-
IT and reporting-control deficiencies
One material weakness involves inadequate IT general controls and related information-produced-by-entity controls, creating transactional and downstream reporting risks as of June 30, 2026.
-
Lack of segregation of duties
The company lacks segregation of duties so information is consistently reviewed and approved by someone other than the preparer; remediation timing remains subject to ongoing evaluation and testing, despite a projected Q4 2026 completion date.
-
No updated risk-factor disclosure
Management stated that there were no material changes to the risk factors previously disclosed in the March 31, 2026 Form 10-K; therefore, no new risk-factor update was identified in this 10-Q.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; the filing discusses only a projected Q4 2026 internal-control remediation date.
Earlier filings 4
10-K · March 31, 2026
Firefly Neuroscience highlights rapid commercial traction in 2025 with Evoke deployed at more than 85 clinical sites and a proprietary EEG/ERP database exceeding 191,000 records, while showing a pronounced revenue…
10-Q · November 12, 2025
Firefly reported Q3 2025 revenue of $388,000 (vs $33,000 in Q3 2024) with gross profit of $146,000 (gross margin 37.6%). The company reduced year‑over‑year operating loss to $(2,656,000) (Q3 2024: $(4,268,000)) but…
10-Q · August 13, 2025
Firefly Neuroscience reported a sharp revenue increase to $299,000 for the quarter ended June 30, 2025 (Q2 2025) versus $10,000 in Q2 2024, driving a 91.6% gross margin. Despite revenue growth and an improved GAAP loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.